Main Industry
Biotechnology
Main Product/Service
REGiMMUNE’s lead product candidate is RGI-2001, a liposomal small-molecule agent designed to expand regulatory T cells for the prevention of acute graft-versus-host disease (aGvHD). The company also is developing antibody and cell-therapy candidates to ei
Founded Year
2018
Unified Business No.
50779876
Status
Active
Number of Employees
0
Total Paid-in
Capital
240,962,510 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). Their mission is: “Delivering breakthrough immune medicines by harnessing the power of regulatory T cells.”
